This is a working overview of circadian rhythm, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-30. Anything still debated is marked as such rather than presented as settled.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
Analytical identification and purity assessment often use high-performance liquid chromatography with ultraviolet detection or mass spectrometry. Liquid chromatography–tandem mass spectrometry is used to detect and quantify SR9009 in biological matrices, including urine and blood, for anti-doping or pharmacokinetic studies. Nuclear magnetic resonance spectroscopy can confirm molecular structure. Stability depends on form and storage: the solid is generally more stable than solutions, and repeated freeze–thaw cycles may degrade samples. Purity is typically reported as a percentage from a certificate of analysis.
Regulatory treatment of SR9009 varies by country and context. It is not approved as a therapeutic drug by agencies such as the United States Food and Drug Administration or the European Medicines Agency. Sports authorities list it as a prohibited substance; the World Anti-Doping Agency classifies it among hormone and metabolic modulators. Legal status for personal possession or sale differs across jurisdictions, and some countries may restrict it under analog or research chemical laws. Buyers who seek verified material often rely on independent laboratory testing because online product labels may not match contents.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ in preclinical models |
| Molecular formula | C20H24ClN3O4S | Reported for the parent compound |
| CAS Registry Number | 1379686-30-2 | Common identifier in chemical databases |
| Appearance | Off-white to pale yellow solid | Typical research chemical solid |
| Solubility | Soluble in DMSO and ethanol; low in water | Class: small organic molecule |
Detection in biological samples can be complicated by rapid metabolism and low circulating concentrations. Some studies report phase I and phase II metabolites, and analytical methods may need to target those species in addition to the parent compound. Immunoassays are not broadly available, so mass spectrometry remains the main confirmatory approach. For anti-doping testing, laboratories look for SR9009 and its metabolites using validated LC-MS methods. Open questions include how long metabolites remain detectable and how different routes of administration alter detection windows.
In laboratory settings, SR9009 is typically characterized by liquid chromatography–mass spectrometry (LC-MS) or high-performance liquid chromatography with ultraviolet detection (HPLC-UV). These methods can confirm identity and estimate purity, but they require reference standards for accurate quantification. Because SR9009 is not a licensed pharmaceutical, no harmonized pharmacopeial monograph exists. Laboratories often validate in-house methods for matrices such as plasma, urine, or cell culture media. Sample preparation may involve protein precipitation or liquid-liquid extraction before analysis.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
In rodent studies, SR9009 has been reported to increase mitochondrial content in skeletal muscle and improve exercise endurance under some conditions. These findings led to popular descriptions such as an exercise mimetic, although that term oversimplifies the biology. Effects vary by dose, timing, tissue, and model. The compound's influence on circadian pathways means that time of administration can matter in experiments. Whether similar metabolic changes occur in humans remains largely unexplored in controlled published trials.
Pharmacokinetic data for SR9009 are limited in published literature. Some reports indicate low oral bioavailability and rapid clearance in animals, which complicates interpretation of exposure and effect. Researchers often use injected routes in preclinical work to achieve measurable systemic levels. Analytical studies rely on mass spectrometry to detect the parent compound and its metabolites. Questions about tissue distribution, active metabolites, and long-term consequences remain open. Species differences in metabolism can affect observed half-life and target engagement.
== Biological function == Although the native biological role of APP is of obvious interest to Alzheimer's research, thorough understanding has remained elusive. Experimental models of Alzheimer's disease are commonly used by researchers to gain better understandings about the biological function of APP in disease pathology and progression.
In the body, stores of fat are referred to as adipose tissue. In these areas, intracellular triglycerides are stored in cytoplasmic lipid droplets. When lipase enzymes are phosphorylated, they can access lipid droplets and through multiple steps of hydrolysis, breakdown triglycerides into fatty acids and glycerol. Each step of hydrolysis leads to the removal of one fatty acid. The first step and the rate-limiting step of lipolysis is carried out by adipose triglyceride lipase (ATGL). This enzyme catalyzes the hydrolysis of triacylglycerol to diacylglycerol. Subsequently, hormone-sensitive lipase (HSL) catalyzes the hydrolysis of diacylglycerol to monoacylglycerol and monoacylglycerol lipase (MGL) catalyzes the hydrolysis of monoacylglycerol to glycerol. Perilipins are proteins that act as a physical shield or dynamic scaffold, preventing lipolytic enzymes in the cytosol from accessing the stored triglycerides during periods of energy abundance. Perilipin 1A is a key protein regulator of lipolysis in adipose tissue. This lipid droplet-associated protein, when deactivated, will prevent the interaction of lipases with triglycerides in the lipid droplet and grasp the ATGL co-activator, comparative gene identification 58 (CGI-58) (a.k.a. ABHD5). When perilipin 1A is phosphorylated by PKA, it releases CGI-58 and it expedites the docking of phosphorylated lipases to the lipid droplet. CGI-58 can be further phosphorylated by PKA to assist in its dispersal to the cytoplasm. In the cytoplasm, CGI-58 can co-activate ATGL.
Regina Nuzzo is a professor of statistics at Gallaudet University in Washington D.C., a liberal arts school for deaf and hard-of-hearing students. She also writes articles about the importance of statistical and science communication and is an advocate for people with disabilities in the science and technology field.
=== Blood === Drug-testing a blood sample measures whether or not a drug or a metabolite is in the body at a particular time. These types of tests are considered to be the most accurate way of telling if a person is intoxicated. Blood drug tests are not used very often because they need specialized equipment and medically trained administrators. Depending on how much marijuana was consumed, it can usually be detected in blood tests within six hours of consumption. After six hours has passed, the concentration of marijuana in the blood decreases significantly. It generally disappears completely within 30 days.
Sources: en.wikipedia.org
== Evolution == Vertebrates started off with a single copy of the vitellogenin gene, and the bird-mammalian and amphibian lineages each experienced duplications that gave rise to the modern genes. With the exception of monotremes, mammals have all their vitellogenin genes turned into pseudogenes, although the region syntenic to bird VIT1-VIT2-VIT3 can still be found and aligned. In monotremes just one of the genes remained functional.
=== Video games === Liches are prominent in the Might and Magic series of video games, appearing primarily as enemies, but also as playable characters in several installments. They are equally prevalent in the spin-off series Heroes of Might and Magic, where they appear in most installments as recruitable creatures, but also as heroes. One of the most prolific liches in New World Computing's old continuity was Sandro, appearing in many titles and referenced in many more. The primary antagonist of Heroes of Might and Magic III: Restoration of Erathia is also a lich: the former king of Erathia raised by necromancers. The Baldur's Gate series of video games includes several liches, as powerful but optional boss fights. Warcraft III and World of Warcraft: Wrath of the Lich King features the continent of Northrend, the realm of the eponymous Lich King and his undead minions. Arthas Menethil, also known as the Lich King, one of the most prominent antagonists in Warcraft lore, appears as a raid boss in the Wrath of the Lich King expansion, as well as a playable character in the crossover video game Heroes of the Storm. In the Dota series of video games, Lich is one of the playable heroes. In League of Legends, the champion Karthus embraced the gift of death and became a lich. In the video game Enter the Gungeon, a lich is the final boss located in Bullet Hell. In Dragon Age: The Veilguard, companion Emmrich Volkarin can become a lich.
== Discovery == German chemist Felix Ehrlich discovered isoleucine while studying the composition of beet-sugar molasses 1903. In 1907 Ehrlich carried out further studies on fibrin, egg albumin, gluten, and beef muscle in 1907. These studies verified the natural composition of isoleucine. Ehrlich published his own synthesis of isoleucine in 1908.
=== Studies of folding with high time resolution === The study of protein folding has been greatly advanced in recent years by the development of fast, time-resolved techniques. Experimenters rapidly trigger the folding of a sample of unfolded protein and observe the resulting dynamics. Fast techniques in use include ultrafast mixing of solutions, photochemical methods, and laser temperature jump spectroscopy. Among the many scientists who have contributed to the development of these techniques are Heinrich Roder, Terry Oas, Harry Gray, Martin Gruebele, Brian Dyer, William Eaton, Sheena Radford, Chris Dobson, Alan Fersht, Bengt Nölting and Lars Konermann.
No more than 5 hydrogen bond donors (the total number of nitrogen–hydrogen and oxygen–hydrogen bonds) No more than 10 hydrogen bond acceptors (all nitrogen or oxygen atoms) A molecular mass less than 500 daltons A calculated octanol-water partition coefficient (Clog P) that does not exceed 5 Note that all numbers are multiples of five, which is the origin of the rule's name. As with many other rules of thumb, such as Baldwin's rules for ring closure, there are many exceptions.
Sources: en.wikipedia.org
Blue fluorescent protein (BFP) is the blue variant of green fluorescent protein (GFP). BFP has a very similar structure to GFP. In the BFP structure, two substitution mutations in the amino acid sequence change its fluorescence from green to blue. The first mutation occurs inside the chromophore of GFP at position 66 which changes a tyrosine to a histidine. The other mutation in BFP is on the tyrosine at position 145 which mutates to phenylalanine. The autocatalytic cyclization and oxidation of the serine, tyrosine, and glycine form the GFP chromophore. These three residues at positions 65-67 make up the green fluorescent chromophore. When the tyrosine in the chromophore is substituted by a histidine, it changes the folding structure of the protein and emission spectra. The T145F mutation is also added to increase the stability of the protein and well as intensify the fluorescence. These mutations are what change GFP to BFP.
Maurice "Moe" Granat (84) (2007) Gladys Millard (87) (2011) Helen Matheson (95) (2011) Mary Zurawinski (96) (2011) Helen Young (90) (2013) Maureen Pickering (79) (2014) While at Caressant Care, Wettlaufer also injected Michael Priddle (63) and Wayne Hedges (57) "with intent to murder". She confessed to two counts of attempted murder in these cases. She left employment at Caressant Care in 2014, but in part-time work at other facilities and at patients' homes, she injected three more people with insulin:
=== Disorders of fluid, electrolyte, and acid-base balance === 276 Disorders of fluid, electrolyte, and acid-base balance 276.0 Hypernatremia 276.1 Hyponatremia 276.2 Acidosis 276.3 Alkalosis 276.4 Mixed acid-base balance disorder 276.5 Dehydration 276.52 Hypovolemia 276.7 Hyperkalemia 276.8 Hypokalemia
StoreDot is a developer of lithium-ion (Li-ion) batteries for electric vehicles founded in 2012 by Doron Myersdorf, Simon Litsyn, and Gil Rosenman. It is based in Herzliya, Israel. The company was founded around developing peptide-based mobile phone displays and data storage. The company reported it was ready to commercially release these products: peptide-based displays by 2016; peptide-based batteries for mobile phones that fully charge in 30 seconds by 2016; germanium-based mobile phone batteries by 2019; electric car and aerial drone batteries that fully charge in five minutes by 2020; scooter batteries that fully charge in under five minutes by 2021; and silicon-graphite-electrode batteries in 2025. None of the aforementioned products have been commercially released as of February 2026. Financial journalists estimated in February 2026 that StoreDot has funding for a few more months of operations. StoreDot stated in 2026 it needs two more years of development in order to commercialize its product.
Sources: en.wikipedia.org
SR9009 is a synthetic small molecule studied as an agonist of the REV-ERB nuclear receptors. It is not an approved medicine, and its effects in humans are not well characterized.
No. It is a synthetic ligand that binds nuclear receptors, not a steroid or peptide hormone. Its activity depends on receptor binding rather than endocrine secretion.
Clinical evidence is limited. Most published data come from cell and animal experiments. Human safety and efficacy remain uncertain.
Legality depends on the country and the intended use. In many places it is sold as a research chemical, but sports and medicine regulations restrict it.